Members |
targetComponentId |
Overlapping malignant neoplasm of female breast |
Malignant neoplasm of overlapping sites of breast (disorder) |
Overlapping malignant neoplasm of ill-defined site |
Malignant neoplastic disease (disorder) |
Overlapping malignant neoplasm of male breast |
Malignant neoplasm of overlapping sites of breast (disorder) |
Overriding right ventriculoarterial valve |
Pulmonary valve overriding ventricular septum (disorder) |
Ovis musimon |
Ovis aries |
Ovotestis |
Ovotesticular disorder of sex development |
Ovula Nabothi |
Retention cyst |
Ovulation temp. chart NOS |
Ovulation temperature chart started |
Ovulation temp. chart NOS |
Ovulation test temperature chart |
Oxacillin sodium 250mg/5mL powder for oral solution |
Product containing precisely oxacillin 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Oxford Knee Score version 1.0 score |
Oxford Knee Score using revised scoring system (observable entity) |
Oxidase |
Oxidase |
Oxo-acid-lyase |
Oxo-acid-lyase |
Oxybuprocaine 0.4% eye drops |
Oxybuprocaine only product |
Oxybuprocaine hydrochloride 0.4% conventional release eye drops |
Oxybuprocaine only product |
Oxybuprocaine hydrochloride 0.4% single-use eye drops |
Oxybuprocaine only product |
Oxybutynin 3.9mg/day transdermal system |
Product containing precisely oxybutynin 162 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
Oxybutynin hydrochloride 15mg m/r tablet |
Oxybutynin only product in oral dose form |
Oxybutynin hydrochloride 15mg prolonged-release oral tablet |
Oxybutynin only product in oral dose form |
Oxycodone hydrochloride 160mg m/r tablet |
Product containing only oxycodone in oral dose form (medicinal product form) |
Oxycodone hydrochloride 160mg prolonged-release oral tablet |
Product containing only oxycodone in oral dose form (medicinal product form) |
Oxygen enrichment therapy NOS |
Oxygen enrichment therapy |
Oxygen enrichment therapy nos |
Oxygen enrichment therapy |
Oxygen saturation above reference range |
Oxygen saturation above reference range |
Oxygenase |
Oxygenase |
Oxymetazoline hydrochloride 0.025% nose drops |
Oxymetazoline hydrochloride 250 microgram/mL nasal solution |
Oxymetazoline hydrochloride 0.05% eye drops |
Oxymetazoline hydrochloride 500 microgram/mL eye solution |
Oxymetazoline hydrochloride 0.05% nose drops |
Oxymetazoline hydrochloride 500 microgram/mL nasal solution |
Oxymorphone 10mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 10mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 20mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 20mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 40mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 40mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 5mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 5mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxytocin 10unt infusion solution 1mL vial |
Product containing precisely oxytocin 10 unit/1 milliliter conventional release solution for injection (clinical drug) |
Oyster - dietary |
Oyster (substance) |
P.M. isolation: organism NOS |
P.M. isolation: organism - finding |
PEG-intron redipen |
Product containing peginterferon alfa-2b (medicinal product) |
PEG-intron redipen 120micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 120 microgram powder for solution for injection pen |
PEG-intron redipen 150micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 150 microgram powder for solution for injection pen |
PEG-intron redipen 50micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 50 microgram powder for solution for injection pen |
PEG-intron redipen 80micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 80 microgram powder for solution for injection pen |
PIE syndrome |
Löffler's syndrome (disorder) |
Packager/labeller NOS |
Packagers/labellers |
Packager/labeller NOS |
Packagers/labellers |
Packing - action |
Insertion - action (qualifier value) |
Paclitaxel 1mcg/mm drug eluting stent |
Paclitaxel 1 microgram/mm2 drug eluting stent (product) |
Pain character NOS |
Pain character - finding |
Pain character NOS |
Pain character |
Pain in limb &/or NOS |
Pain in limb |
Pain in limb &/or NOS |
Pain in limb |
Pain in limb NOS |
Pain in limb |
Pain in limb NOS |
Pain in limb |
Pain of oral cavity structure |
Pain of region of internal part of mouth (finding) |
Painful ejaculation |
Painful ejaculation |
Painter/coater NOS |
Painters/coaters |
Painter/coater NOS |
Painters/coaters |
Painting of female perineal warts |
Painting of perineal warts (procedure) |
Palatal flap |
Flap (substance) |
Palatoplasty |
Uvulopalatopharyngoplasty |
Pale faeces |
Pale feces |
Pale faeces |
Pale feces |
Pale feces symptom |
Pale feces |
Pale red color |
Pale red colour |
Palpitations NOS |
Palpitations |
Palpitations NOS |
Palpitations |
Pamidronate disodium 3mg/mL infusion concentrate 5mL vial |
Product containing precisely disodium pamidronate 3 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Pancreas excision |
Pancreatectomy |
Pancreas operations NOS |
Operation on pancreas |
Pancreas operations NOS |
Operation on pancreas |
Pancreatectomy NEC |
Pancreatectomy |
Pancreatectomy NEC |
Pancreatectomy |
Pancrelipase, amylase:lipase 183.49mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 184.84mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 210.33mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 278.72% capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 312.17mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 346.86mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 4500unit capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 62.81% |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 62.81% capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 94.3mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pantoprazole sodium 40mg injection |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Pantoprazole sodium 40mg m/r tablet |
Pantoprazole (as pantoprazole sodium) 40 mg gastro-resistant oral tablet |
Pantoprazole sodium 40mg powder |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Pantoprazole sodium 40mg/vial powder for injection |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Papain specific extract |
Product containing papain (medicinal product) |
Papaya - dietary |
Papaya |
Paper/board processor NOS |
Paper and board processor |
Paper/board processor NOS |
Paper and board processor |
Paphosia adorabilis |
Lophornis adorabilis (organism) |
Papillary cystadenoma, borderline malignancy |
Papillary cystadenoma, borderline malignancy |
Papillary cystic tumour |
Primary malignant solid pseudopapillary neoplasm of pancreas (disorder) |
Papillary mucinous cystadenoma, borderline malignancy |
Papillary mucinous cystadenoma, borderline malignancy |
Papillary serous cystadenocarcinoma |
Serous cystadenocarcinoma |
Papillary serous cystadenoma, borderline malignancy |
Serous papillary cystic tumour of borderline malignancy |
Papilloma, no International Classification of Diseases for Oncology subtype (except papilloma of bladder M-81201) |
Benign papilloma (morphologic abnormality) |
Para-aminophenol derivative anti-inflammatory agent |
Para-aminophenol derivative |
Paracetamol + chlorpheniramine maleate + phenylephrine hydrochloride 500mg/8mg/40mg |
Product containing only chlorphenamine and paracetamol and phenylephrine (medicinal product) |